De novo metastatic castration sensitive prostate cancer: State of art and future perspectives

Area of Science:

• Oncology
• Urology

Background:

• De novo metastatic castration-sensitive prostate cancer (mCSPC) presents heterogeneous clinical and biological behaviors.
• Androgen deprivation therapy (ADT) was the standard of care, but recent evidence supports adding chemotherapy (docetaxel) or abiraterone acetate.

Purpose of the Study:

• To review the current understanding of de novo mCSPC, including clinical presentation, prognostic classification, and available therapies.
• To highlight ongoing clinical trials and future directions for managing de novo mCSPC.

Main Methods:

• Literature review of clinical presentation, prognostic stratification, and therapeutic options for de novo mCSPC.
• Analysis of recent advancements and evidence supporting new treatment modalities.

Main Results:

• The therapeutic landscape for mCSPC has expanded with effective additions to ADT.
• Prognostic stratification and optimal therapeutic strategies for de novo mCSPC require further prospective definition.

Conclusions:

• Current evidence supports enhanced treatment regimens for de novo mCSPC.
• Further research and clinical trials are essential to refine prognostic models and personalize treatment approaches for de novo mCSPC.